This company listing is no longer active
Ina Research Past Earnings Performance
Past criteria checks 0/6
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Next Earnings Update | 10 Aug 2022 |
Recent past performance updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Ina Research has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How Ina Research makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 18 | 2,425 | 141 | 476 | 38 |
| 31 Dec 17 | 2,556 | 256 | 448 | 43 |
| 30 Sep 17 | 2,298 | 138 | 455 | 43 |
| 30 Jun 17 | 2,198 | 72 | 480 | 43 |
| 31 Mar 17 | 2,295 | 31 | 483 | 43 |
| 31 Dec 16 | 2,057 | -649 | 431 | 100 |
| 30 Sep 16 | 2,451 | -557 | 433 | 100 |
| 30 Jun 16 | 2,245 | -1,110 | 416 | 100 |
| 31 Mar 16 | 2,116 | -1,204 | 469 | 100 |
| 31 Dec 15 | 2,594 | -628 | 533 | 65 |
| 30 Sep 15 | 2,381 | -681 | 544 | 65 |
Quality Earnings: Insufficient data to determine if 2176 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if 2176's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2176's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare 2176's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if 2176's earnings growth over the past year exceeded the Life Sciences industry average.
Return on Equity
High ROE: 2176 has a negative Return on Equity (0%), as it is currently unprofitable.